Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug;100(2):314-9.
doi: 10.1016/j.radonc.2011.03.005. Epub 2011 Apr 16.

Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study

Gero Wieners  1 , Konrad Mohnike, Nils Peters, Joachim Bischoff, Anke Kleine-Tebbe, Ricarda Seidensticker, Max Seidensticker, Günther Gademann, Peter Wust, Maciej Pech, Jens Ricke
Affiliations
Clinical Trial

Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study

Gero Wieners et al. Radiother Oncol. 2011 Aug.

Abstract

Purpose: The aim of the study was the evaluation of feasibility, safety and effectiveness of interstitial brachytherapy for the treatment of hepatic metastases of breast cancer.

Materials and methods: Forty-one consecutive patients with 115 unresectable hepatic metastases of breast cancer were included in this phase-II-trial. They were treated in 69 interventions of CT-guided-interstitial-brachytherapy of the liver. Brachytherapy was applied as a single fraction high-dose-irradiation (15-25Gy (Gray)) using a (192)Ir-source of 10Ci. Nineteen patients presented systemically pretreated extrahepatic tumors. Primary endpoints were complications, local tumor control and progression-free survival.

Results: The median tumor diameter was 4.6 cm (1.5-11 cm). The median irradiation time per intervention was 26.5 min (range: 7-47 min). The applied median minimal dose at the CTV (clinical target volume) margin was 18.5 Gy (12-25 Gy). In 69 interventions and during the postinterventional period, one major complication (symptomatic post-interventional bleeding) (1.5%) and six minor complications occurred (8.7%). The median follow-up time was 18 months (range: 1-56). After 6, 12 and 18 months, local tumor control was 97%, 93.5% and 93.5%, intra- and extrahepatic progression free survival was 53%, 40% and 27%, and overall survival was 97%, 79% and 60%, respectively.

Conclusion: CT-guided-brachytherapy is safe and effective for the treatment of liver metastases of breast cancer.

PubMed Disclaimer

Publication types